Latest News
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
22 September 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Tuesday it has received European Commission approval for RINVOQ (upadacitinib) to treat active polyarticular juvenile idiopathic arthritis in patients aged two years and old...
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
22 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Tuesday reported positive topline Phase II results for enicepatide, an investigational once-weekly dual GLP-1/GIP receptor agonist, in ...
Pharming reports positive Phase II data for leniolisib in primary immunodeficiencies
22 September 2026 - Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam:PHARM) (NASDAQ:PHAR) on Tuesday announced positive topline Phase II data for leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dy...
Clene Inc closes registered direct offering of common stock to existing shareholders
22 September 2026 - Clene Inc (Nasdaq:CLNN), a clinical-stage biotechnology company focused on amyotrophic lateral sclerosis (ALS), announced on Monday the closing of a registered direct offering of common stock to existing shareholders, including in...
AbbVie and Iambic agree collaboration for discovery and development of small molecule therapies
22 September 2026 - US pharmaceutical company AbbVie (NYSE:ABBV), and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and development platform, announced on Monday a multi-year ...